Paper of the Month - July, 2011

0 rating

Adjuvant docetaxel for high-risk, node-negative breast cancer.

Martín M, Seguí MA, Antón A et al.
Professor Martín’s previous study, BCIRG 001 (Breast Cancer International Research Group 001), clearly demonstrated the benefits of docetaxel as adjuvant chemotherapy when substituted for 5-fluorouracil in the FAC regimen.


READER POLL

Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE